Development of a combination antibiogram for Pseudomonas aeruginosa bacteremia in an oncology population

Abstract

Purpose

Development of a combination antibiogram to identify combinations of antibiotics that have the highest likelihood of attaining one active agent in the empiric management of presumed Pseudomonas aeruginosa bacteremia.

Methods

Patients with cancer and P. aeruginosa bacteremia from January 1 to December 31, 2012 were included in this analysis. The primary outcome was identification of effective combinations of beta-lactam and non-betalactam agents. An effective combination was defined as one which achieved in-vitro activity to greater than or equal to 85% of isolates collected. Furthermore, the addition of the non-beta-lactam agent was required to increase the in-vitro activity by at least 5% over beta-lactam monotherapy. Multiple secondary outcomes were evaluated.

Results

One hundred and twenty-three P. aeruginosa isolates were included from 99 patients. Single agent beta-lactam sensitivities ranged from 72.4 to 79.7%. Combination regimen sensitivities ranged from 73.5 to 96.7%. All combination regimens that included a beta-lactam plus an aminoglycoside were found to be effective per the study definition. Independent risk factors for MDR P. aeruginosa were receipt of intravenous (IV) antibiotics within 90 days and hospital length of stay (LOS) greater than or equal to five days. Increasing the number of antibiotics received was associated with a decrease in survival to hospital discharge.

Conclusions

Effective combination regimens included all beta-lactam aminoglycoside regimens. Receipt of IV antibiotics within 90 days and hospital LOS greater than or equal to five days were independent risk factors for MDR isolates.

Keywords

drug therapy combination pseudomonas aeruginosa cancer population bacteremia anti-bacterial agents

Get full access to this article

View all access options for this article.

References

Kumar

Roberts

Wood

. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589–1596.

Kumar

Ellis

Arabi

. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009; 136: 1237–1248.

Micek

Welch

Khan

. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. Antimicrob Agent Chemother 2010; 54: 1742–1748.

Kumar

Safdar

Kethireddy

. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study. Crit Care Med 2010; 38: 1651–1664.

Dellinger

Levy

Rhodes

. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41: 580–637.

Parkins

Gregson

Pitout

. Population-based study of the epidemiology and the risk factors for Pseudomonas aeruginosa bloodstream infection. Infection 2010; 38: 25–32.

Williams

Braun

Cooper

. Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care. Crit Care 2004; 8: R291–R298.

Mizuta

Linkin

Nachamkin

. Identification of optimal combinations for empirical dual antimicrobial therapy of Pseudomonas aeruginosa infection: potential role of a Combination Antibiogram. Infect Control Hosp Epidemiol 2006; 27: 413–415.

Apisarnthanarak

Mundy

. Role of combination antibiogram in empirical treatment of infection due to multidrug-resistant Acinetobacterbaumannii. Infect Control Hosp Epidemiol 2008; 29: 678–679.

10.

Christoff

Tolentino

Mawdsley

. Optimizing empirical antimicrobial therapy for infection due to gram-negative pathogens in the intensive care unit: utility of a combination antibiogram. Infect Control Hosp Epidemiol 2010; 31: 256–261.

11.

Beardsley

Williamson

Johnson

. Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. Chest 2006; 130: 787–793.

12.

Hindler

Stelling

. Analysis and presentation of cumulative antibiograms: a new consensus guideline from the Clinical and Laboratory Standards Institute. Clin Infect Dis 2007; 44: 867–873.

13.

Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty-second informational supplement. M100-S22 , Clinical Wayne, PA: Laboratory Standards Institute, 2012.

14.

Johnson

Reichley

Hoppe-Bauer

. Impact of previous antibiotic therapy on outcome of Gram-negative severe sepsis. Crit Care Med 2011; 39: 1859–1865.

15.

Kumar

Zarychanski

Light

. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 2010; 38: 1773–1785.

16.

Safdar

Handelsman

Maki

. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4: 519–527.

17.

Morata

Cobos-Trigueros

Martínez

. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2012; 56: 4833–4837.

18.

Tam

Rogers

Chang

. Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother 2010; 54: 3717–3722.

19.

Magiorakos

Srinivasan

Carey

. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268–281.

20.

Kang

Kim

Park

. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005; 49: 760–766.

21.

Neuhauser

Weinstein

Rydman

. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003; 289: 885–888.

22.

Loo

Bourgault

Poirier

. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011; 365: 1693–1703.

23.

Falagas

Rafailidis

Kofteridis

. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother 2007; 60: 1124–1130.

24.

American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388–416.